Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
DAVID B. WEINER · INTERNATIONAL SOCIETY OF VACCINES · 2023 · $5,000 — Project Summary / Abstract The International Society for Vaccines (ISV) is a not-for-profit membership organization founded in 1992 with members from 44 countries, holding annual congresses since 2007. With the ISV Annual Congress, attended by member and non-member participants from 5 continents, th…
Sean PJ Whelan · WASHINGTON UNIVERSITY · 2023 · $561,330 — This application is to extend a MERIT award to study RNA synthesis in minus-strand RNA viruses. Nonsegmented negative-sense (NNS) RNA viruses include some of the most significant human pathogens that are an ongoing threat to US public health. For measles, mumps and rabies there are licensed vaccines…
Xiaorong Lin · UNIVERSITY OF GEORGIA · 2023 · $166,248 — Cryptococcus neoformans and C. gattii cause life threatening cryptococcal meningoencephalitis, the most common fungal infection of the central nervous system in the world today. The 12-month mortality rate for individuals with cryptococcal meningoencephalitis is 60% even with the current antifungal …
THOMAS MELENDY · STATE UNIVERSITY OF NEW YORK AT BUFFALO · 2023 · $199,375 — Project Summary/Abstract: Effective antivirals are sorely needed against SARS CoV-2 (CoV2), and coronaviruses (CoV) in general. Screening systems for drugs targeting CoV2 enzymes usually involve screening against purified enzymes. This can be technically challenging, and the vast majority of inhibit…
YASUHIRO SUZUKI · UNIVERSITY OF KENTUCKY · 2023 · $459,000 — Chronic infection with Toxoplasma gondii can reactivate and cause life-threatening toxoplasmic encephalitis in AIDS patients and other immunocompromised individuals. The basis of persistence of this chronic infection is the tissue cyst. Thus, eliminating T. gondii cysts from chronically infected ind…
MATTHEW TIRRELL · UNIVERSITY OF CHICAGO · 2023 · $797,003 — Project Summary This R01 proposal outlines a research plan which uses targeted nanomedicine to enhance disease- modifying molecular mechanisms both in the acute injurious phase and in the subsequent chronic fibrotic phase of viral-induced pneumonitis. The overall goal of this proposal is to use nan…
George B Sigal · MESO SCALE DIAGNOSTICS, LLC · 2023 · $842,062 — Our objective is to develop better assays for measuring antibodies produced in people after influenza infection or vaccination. We’ll develop assays that measure total antibody responses, and assays that specifically measure the antibodies responsible for protection from infection. By using high-thr…
Richard John Martin · IOWA STATE UNIVERSITY · 2023 · $469,119 — Project Summary Filariases are a group of neglected tropical diseases produced by infection with microfilaria of Clade III parasitic nematodes that are transmitted by biting insects. One example is the lymphatic filariasis produced by Brugia malayi. Lymphatic filariasis is a debilitating and disfigu…
ERIC T. KOOL · STANFORD UNIVERSITY · 2023 · $623,371 — Work in the last decade from many labs has underlined the critical importance of RNA-mediated cellular pathways, and clear connections of specific RNAs to human health. RNAs are increasingly viewed both as appealing therapeutic targets, and as therapeutic agents themselves. We hypothesize that obtai…
STEVEN GREGORY REED · HDT BIO CORPORATION · 2023 · $538,074 — PROJECT SUMMARY/ABSTRACT Our team - in collaboration with other vaccine developers - has been actively involved in tuberculosis (TB) vaccine discovery for the past three decades and led the team that developed the M72 vaccine that has provided proof of concept for effective subunit TB vaccines. Obst…
Javeed Ali Shah · UNIVERSITY OF WASHINGTON · 2023 · $256,475 — Project Summary/Abstract. Over one million people died from tuberculosis in 2021. Current treatments are long, costly, and often induce severe adverse effects, but the current vaccine has not been improved in over 100 years. Improved understanding of the host factors that influence Mtb pathogenesis …
RONALD LEVY · STANFORD UNIVERSITY · 2023 · $514,997 — Project Summary: Cancer is a leading global cause of mortality. The goal of this multi-disciplinary project is to pre-clinically advance a novel concept for selective and efficient mRNA delivery that enables a highly promising vaccination strategy for cancer immunotherapy. Given the potential of can…
Parisa Yousefpour · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · 2023 · $73,772 — PROJECT SUMMARY Infectious diseases such as HIV, malaria, tuberculosis, and seasonal influenza epidemics and emergence of new pandemics remain major global health problems highlighting the need for innovative approaches in vaccine design. The precise kinetics of antigen exposure relative to inflamma…
Elena Vassilieva · EMORY UNIVERSITY · 2023 · $195,625 — PROJECT SUMMARY Severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2) is currently causing the coronavirus disease (COVID-19) in pandemic proportion. According to John Hopkins university data tracker, there were 120,217,175 global cases and 2,660,456 deaths worldwide on March 15, 2021. The d…
James D. Bryers · UNIVERSITY OF WASHINGTON · 2023 · $540,184 — While Staphylococcus aureus (SA) commonly asymptomatically colonizes the skin and nose of healthy humans, severe disease can result from infection of the blood, bone, skin, and lungs, as well as sites of catheters and prosthetic devices. With currently approved therapy, about one-third of patients d…
Rajesh Thippeshappa · TEXAS BIOMEDICAL RESEARCH INSTITUTE · 2023 · $378,000 — Abstract/Summary: Commonly used animal models of HIV-1 include infection of macaques with Simian Immunodeficiency Virus (SIV) or Simian-Human Immunodeficiency Virus (SHIV) containing HIV envelope (Env) or reverse transcriptase. These animal models have been extremely useful in understanding HIV path…
Vitaly V. Ganusov · UNIVERSITY OF TENNESSEE KNOXVILLE · 2023 · $570,739 — Research Summary Tuberculosis (TB), a disease caused by the bacteria Mycobacterium tuberculosis (Mtb), remains a major infec- tious disease of humans in the world. After the initial local infection of one site in the lung Mtb somehow dissem- inates in the lung and often spreads beyond the lung. In f…
Yamin Li · UPSTATE MEDICAL UNIVERSITY · 2023 · $81,500 — SUMMARY The mRNA-based therapeutics has wide applications in disease prevention and treatment. However, its wide practical application is largely limited by the delivery concerns. Cationic lipids are effective carrier materials for mRNA delivery and the chemical structure of lipid molecules is criti…
Sarah Elizabeth Walker · STATE UNIVERSITY OF NEW YORK AT BUFFALO · 2023 · $333,429 — SUMMARY: The level of each protein synthesized in a cell results from both the amount of mRNA available, and the number of ribosomes that initiate translation of that mRNA. Eukaryotic translation initiation factors (eIFs) can reprogram which mRNAs are available and translated to produce different le…
KENT E. KESTER · INTERNATIONAL AIDS VACCINE INITIATIVE · 2023 · $422,266 — Project Summary/Abstract Tuberculosis remains one of the top ten leading causes of death worldwide (1). Based on the most current information from WHO 2020 report, in 2019 an estimated 1.4 million people died from TB and approximately 10,000,000 fell ill (2). The COVID-19 pandemic has led to massive…